Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Latest quote
$26.96
+$0.07 · +0.26%
After-hours
$26.90
−$0.06 · -0.22%
Oct 8, 5:36 PM ET
Regular session · ET · Market data may be delayed.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Day range
Current $26.96
52-week range
Current $26.96
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
88
Deep Value
Sentiment
58
Mixed
Risk
32
Moderate Risk
Momentum
45
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Day range
Current $26.96
52-week range
Current $26.96
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6.16B USD | 5.81B USD | 5.55B USD | 5.22B USD | 5.21B USD |
| Cost of goods sold | 1.96B USD | 1.73B USD | 1.65B USD | 1.52B USD | 1.51B USD |
| Gross profit | 4.21B USD | 4.08B USD | 3.9B USD | 3.7B USD | 3.7B USD |
| Research and development | 346M USD | 343M USD | 339M USD | 345M USD | 356M USD |
| Selling, general, and administrative | 3.04B USD | 2.9B USD | 2.83B USD | 2.71B USD | 2.64B USD |
| Operating expenses | 3.41B USD | 3.42B USD | 3.47B USD | 3.25B USD | 3.11B USD |
| Interest income | 28.07M USD | 24.01M USD | 34.13M USD | 13.99M USD | 6M USD |
| Interest expense | 141.33M USD | 150.06M USD | 132.51M USD | 79.95M USD | 79.99M USD |
| Depreciation and amortization | 573M USD | 555M USD | 527M USD | 548M USD | 563M USD |
| Operating income | 794M USD | 657M USD | 425M USD | 450M USD | 593M USD |
| Net income | 625M USD | 412M USD | 263M USD | 223M USD | 524M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$31.91
18.36% upsideCash distributions grouped by calendar year; partial years are marked.
$0.762
2025 complete year+1.6% since 2021
2026 partial: $0.794
$0.75
2,021
$0.75
2,022
$0.75
2,023
$0.75
2,024
$0.762
2,025
$0.794
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Oct 2, 2026 | $0.312Semi-Annual | Oct 2, 2026 | Nov 6, 2026 |
Dividend | Mar 27, 2026 | $0.482Semi-Annual | Mar 27, 2026 | May 27, 2026 |
Dividend | Oct 3, 2025 | $0.30Semi-Annual | Oct 3, 2025 | Nov 7, 2025 |
Dividend | Mar 28, 2025 | $0.462Semi-Annual | Mar 28, 2025 | May 28, 2025 |
Dividend | Oct 4, 2024 | $0.288Semi-Annual | Oct 4, 2024 | Nov 8, 2024 |
Dividend | Apr 1, 2024 | $0.462Semi-Annual | Apr 2, 2024 | May 22, 2024 |
Ex-dividend Oct 2, 2026
$0.312
Semi-Annual
Record Oct 2, 2026 · Payment Nov 6, 2026
Ex-dividend Mar 27, 2026
$0.482
Semi-Annual
Record Mar 27, 2026 · Payment May 27, 2026
Ex-dividend Oct 3, 2025
$0.30
Semi-Annual
Record Oct 3, 2025 · Payment Nov 7, 2025
Ex-dividend Mar 28, 2025
$0.462
Semi-Annual
Record Mar 28, 2025 · Payment May 28, 2025
Ex-dividend Oct 4, 2024
$0.288
Semi-Annual
Record Oct 4, 2024 · Payment Nov 8, 2024
Ex-dividend Apr 1, 2024
$0.462
Semi-Annual
Record Apr 2, 2024 · Payment May 22, 2024
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Total International Stock ETFVXUS10.71M0.00%665.7B USD0.05%$84.10-0.81%
Vanguard FTSE Emerging Markets ETFVWO10.45M0.01%168.5B USD0.06%$59.10-1.25%
Dimensional - International Core Equity 2 ETFDFIC8M0.05%15.01B USD0.22%$37.29-0.13%
Avantis International Equity ETFAVDE7.33M0.04%19.02B USD0.23%$89.28-0.22%
Dimensional World ex U.S. Core Equity 2 ETFDFAX4.87M0.04%12.37B USD0.28%$36.80-0.76%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP2.18M0.08%2.69B USD0.20%$65.61-1.19%
Vanguard FTSE All-World ex-US ETFVEU1.72M0.00%98.6B USD0.04%$82.18-0.81%
Vanguard International High Dividend Yield ETFVYMI858.89K0.00%22.8B USD0.07%$100.06-0.17%
Vanguard Total International Stock ETFVXUS
Vanguard FTSE Emerging Markets ETFVWO
Dimensional - International Core Equity 2 ETFDFIC
Avantis International Equity ETFAVDE
Dimensional World ex U.S. Core Equity 2 ETFDFAX
State Street SPDR S&P Kensho New Economies Composite ETFKOMP
Vanguard FTSE All-World ex-US ETFVEU
Vanguard International High Dividend Yield ETFVYMIAI-generated and delayed market data for informational and educational purposes only. Not investment advice.